These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 19995961)

  • 21. Modulation of host metabolism as a target of new antivirals.
    Ikeda M; Kato N
    Adv Drug Deliv Rev; 2007 Oct; 59(12):1277-89. PubMed ID: 17897752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advances in hepatitis C: what is coming in the next 5 years?
    Locarnini SA; Bartholomeusz A
    J Gastroenterol Hepatol; 2002 Apr; 17(4):442-7. PubMed ID: 11982725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The molecular biology of hepatitis C virus].
    Koutsoudakis G; Forns X; Pérez-Del-Pulgar S
    Gastroenterol Hepatol; 2013 Apr; 36(4):280-93. PubMed ID: 23490024
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Experimental models for hepatitis C virus (HCV): new opportunities for combating hepatitis C.
    Trujillo-Murillo Kdel C; Garza-Rodríguez Mdel L; Martínez-Rodríguez HG; Barrera-Saldaña HA; Bosques-Padilla F; Ramos-Jiménez J; Rivas-Estilla AM
    Ann Hepatol; 2004; 3(2):54-62. PubMed ID: 15257247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Entry inhibitors: New advances in HCV treatment.
    Qian XJ; Zhu YZ; Zhao P; Qi ZT
    Emerg Microbes Infect; 2016 Jan; 5(1):e3. PubMed ID: 26733381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methanolic Extract of
    Hung TC; Jassey A; Lin CJ; Liu CH; Lin CC; Yen MH; Lin LT
    Viruses; 2018 Nov; 10(12):. PubMed ID: 30486350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus.
    Vausselin T; Séron K; Lavie M; Mesalam AA; Lemasson M; Belouzard S; Fénéant L; Danneels A; Rouillé Y; Cocquerel L; Foquet L; Rosenberg AR; Wychowski C; Meuleman P; Melnyk P; Dubuisson J
    J Virol; 2016 Oct; 90(19):8422-34. PubMed ID: 27412600
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from
    Sahuc ME; Sahli R; Rivière C; Pène V; Lavie M; Vandeputte A; Brodin P; Rosenberg AR; Dubuisson J; Ksouri R; Rouillé Y; Sahpaz S; Séron K
    J Virol; 2019 May; 93(10):. PubMed ID: 30842319
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Molecular mechanisms of hepatitis C virus (HCV) replication - implications for the development of antiviral drugs].
    Bühler S; Bartenschlager R
    Z Gastroenterol; 2011 Jul; 49(7):836-44. PubMed ID: 21766263
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Antiviral agents for analyzing virus life cycle: chemical genetics for virology].
    Watashi K
    Yakugaku Zasshi; 2013; 133(11):1169-75. PubMed ID: 24189558
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Current approaches for developing new anti-HCV agents and analyses of HCV replication using anti-HCV agents].
    Watashi K; Shimotohno K
    Uirusu; 2005 Jun; 55(1):105-10. PubMed ID: 16308536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting HIV/HCV Coinfection Using a Machine Learning-Based Multiple Quantitative Structure-Activity Relationships (Multiple QSAR) Method.
    Wei Y; Li W; Du T; Hong Z; Lin J
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336592
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a cell-based assay for high-throughput screening of inhibitors against HCV genotypes 1a and 1b in a single well.
    Mondal R; Koev G; Pilot-Matias T; He Y; Ng T; Kati W; Molla A
    Antiviral Res; 2009 Apr; 82(1):82-8. PubMed ID: 19174175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. (4R,6S)-2-Dihydromenisdaurilide is a Butenolide that Efficiently Inhibits Hepatitis C Virus Entry.
    Chung CY; Liu CH; Wang GH; Jassey A; Li CL; Chen L; Yen MH; Lin CC; Lin LT
    Sci Rep; 2016 Jul; 6():29969. PubMed ID: 27426693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Screening for hepatitis C virus antiviral activity with a cell-based secreted alkaline phosphatase reporter replicon system.
    Bourne N; Pyles RB; Yi M; Veselenak RL; Davis MM; Lemon SM
    Antiviral Res; 2005 Aug; 67(2):76-82. PubMed ID: 15927278
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging therapeutic strategies for hepatitis C virus infection.
    Sato K; Takagi H; Ichikawa T; Kakizaki S; Mori M
    Curr Mol Pharmacol; 2008 Jun; 1(2):130-50. PubMed ID: 20021428
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-throughput approaches to unravel hepatitis C virus-host interactions.
    Colpitts CC; El-Saghire H; Pochet N; Schuster C; Baumert TF
    Virus Res; 2016 Jun; 218():18-24. PubMed ID: 26410623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatitis C virus virology and new treatment targets.
    Meier V; Ramadori G
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):329-50. PubMed ID: 19344246
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of a cell-based hepatitis C virus infection fluorescent resonance energy transfer assay for high-throughput antiviral compound screening.
    Yu X; Sainz B; Uprichard SL
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4311-9. PubMed ID: 19620334
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Priming of Antiviral CD8 T Cells without Effector Function by a Persistently Replicating Hepatitis C-Like Virus.
    Hartlage AS; Walker CM; Kapoor A
    J Virol; 2020 May; 94(10):. PubMed ID: 32102885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.